Year-ender: China's sci-tech achievements in 2022
chinadaily.com.cn |
Updated: 2022-12-26 06:40
Share
Share - WeChat
First homegrown antiviral joins virus battle
On July 25, China's first domestically developed COVID-19 antiviral Azvudine obtained emergency use authorization from the National Medical Products Administration, China's top drug regulator, and was included in the latest COVID-19 diagnosis and treatment guideline on Aug 9.
The oral drug, developed by the Genuine Biotech Co based in Henan province, contains 35 tablets per bottle with 1 milligram per tablet.
The guideline stipulates that the drug will be used to treat adult COVID-19 patients with moderate symptoms.
Azvudine was first approved in July 2021 to treat HIV patients, and was also found to be promising in tackling COVID-19.
